摘要
本文分析了专利药品进入基本药物目录在提高居民用药层次、保证药品可及性方面的积极意义以及该做法在支付能力和专利时效性方面所面临的挑战。建议在政府财政和医保基金的可承受范围内,通过价格谈判机制和基本药物目录的动态调节机制来降低专利药品价格,并使专利药品进入基本药物目录变为常态,成为我国基本药物目录动态管理的一部分。
The paper analyses the significance of patent medicines being listed into the essential medicine list, in terms of improving residents＇ medication level and the access to medicine, as well as its challenges on the afford- ability and timeliness of patent medicines. In this paper, we suggest that a negotiation mechanism should be estab- lished and be dynamically adjusted to decease the price of patient medicine within financing ability and the affordable insurance funds. In other words, this enables to make it a normal condition to get the patient medicine integrated into the essential medicine list. In turn, it could dynamically administer the essential medicine list in China.
出处
《中国卫生政策研究》
2012年第7期31-34,共4页
Chinese Journal of Health Policy
关键词
基本药物目录
动态管理
专利药品
价格谈判
Essential medicine list
Dynamic administration
Patent medicine
Plaice negotiation
